Completed PHASE3 INTERVENTIONAL NCT00218192

A Trial to Reduce Hepatitis C Among Injection Drug Users - 1

A Trial to Reduce Hepatitis C Among Injection Drug Users

Sponsor: Butler Hospital

Conditions HCV Negative Status HCV Risk Behavior

Updated 5 times since 2017 Last updated: May 21, 2015 Started: Sep 30, 2000 Primary completion: Nov 30, 2006 Completion: Nov 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00218192, this PHASE3 trial focuses on HCV Negative Status and HCV Risk Behavior and remains completed. Sponsored by Butler Hospital, it has been updated 5 times since 2000, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Sep 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Butler Hospital
National Institute on Drug Abuse (NIDA)

Data source: Butler Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Providence, United States